MAP4343 Treatment for Alcohol Use Disorder

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Alcohol Use Disorder
Interventions
DRUG

MAP4343

Subjects will receive daily oral doses of MAP4343 for 6 weeks in conjunction with 6 weeks of manual-guided counseling

DRUG

Placebo

Subjects receive matched placebo for 6 weeks in conjunction with 6 weeks of manual-guided counseling

BEHAVIORAL

Standardized behavioral counseling

Subjects receive manually-guided counseling 1 time per week for a 6 week duration

Trial Locations (1)

92037

The Scripps Research Institute Pearson Center for Alcoholism and Addiction Research, La Jolla

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

collaborator

Mapreg

INDUSTRY

lead

The Scripps Research Institute

OTHER

NCT04157114 - MAP4343 Treatment for Alcohol Use Disorder | Biotech Hunter | Biotech Hunter